07-02-2023, 09:46 AM
Q: How long will the Pfizer-BioNTech COVID-19 Vaccine provide protection?
A: Data are not yet available to inform about the duration of protection that the vaccine will provide.
Q: Does Pfizer-BioNTech COVID-19 Vaccine protect against asymptomatic SARS-CoV-2 infection? (Asymptomatic infection is when someone is infected with SARS-CoV-2 but does not have signs or symptoms of COVID-19.)
A: It is not known if Pfizer-BioNTech COVID-19 Vaccine protects against asymptomatic SARS-CoV-2 infection.
Q: If a person has received the Pfizer-BioNTech COVID-19 Vaccine, will the vaccine protect against transmission of SARS-CoV-2 from individuals who are infected despite vaccination?
A: Most vaccines that protect from viral illnesses also reduce transmission of the virus that causes the disease by those who are vaccinated. While it is hoped this will be the case, the scientific community does not yet know if the Pfizer-BioNTech COVID-19 Vaccine will reduce such transmission.
Q. What information is available about myocarditis and pericarditis following vaccination with Pfizer-BioNTech COVID-19 Vaccine?
A. Post-authorization safety surveillance data pertaining to myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the tissue surrounding the heart) demonstrate increased risks of myocarditis and pericarditis, particularly within 7 days following the second dose of the Pfizer-BioNTech COVID-19 Vaccine, with the observed risk being higher in males under 40 years of age than in females or older males. The observed risk is highest in males 12 through 17 years of age.
https://www.fda.gov/emergency-preparedne...-questions
A: Data are not yet available to inform about the duration of protection that the vaccine will provide.
Q: Does Pfizer-BioNTech COVID-19 Vaccine protect against asymptomatic SARS-CoV-2 infection? (Asymptomatic infection is when someone is infected with SARS-CoV-2 but does not have signs or symptoms of COVID-19.)
A: It is not known if Pfizer-BioNTech COVID-19 Vaccine protects against asymptomatic SARS-CoV-2 infection.
Q: If a person has received the Pfizer-BioNTech COVID-19 Vaccine, will the vaccine protect against transmission of SARS-CoV-2 from individuals who are infected despite vaccination?
A: Most vaccines that protect from viral illnesses also reduce transmission of the virus that causes the disease by those who are vaccinated. While it is hoped this will be the case, the scientific community does not yet know if the Pfizer-BioNTech COVID-19 Vaccine will reduce such transmission.
Q. What information is available about myocarditis and pericarditis following vaccination with Pfizer-BioNTech COVID-19 Vaccine?
A. Post-authorization safety surveillance data pertaining to myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the tissue surrounding the heart) demonstrate increased risks of myocarditis and pericarditis, particularly within 7 days following the second dose of the Pfizer-BioNTech COVID-19 Vaccine, with the observed risk being higher in males under 40 years of age than in females or older males. The observed risk is highest in males 12 through 17 years of age.
https://www.fda.gov/emergency-preparedne...-questions